^
Association details:
| Biomarker: | Chr t(8;21) + KIT mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Repurposing cabozantinib with therapeutic potential in KIT-driven t(8;21) acute myeloid leukaemias
Published date:
04/08/2021
Excerpt:
In a mouse xenograft model, cabozantinib suppressed tumourigenesis at 10 mg/kg and significantly prolonged survival of the mice....cabozantinib may be effective in the treatment of AML with t(8;21) and KIT mutation.
DOI:
https://doi.org/10.1038/s41417-021-00329-1
